Follistatin 344 is an investigational compound. There is no FDA-approved injectable follistatin drug, and the strongest human evidence comes from a small number of gene therapy trials, not from the vials sold online. Every claim below is sourced. Check the numbers yourself if you want. Last reviewed: June 2026.
Here’s the job you’re actually trying to do: get muscle to grow past the point your own body normally allows. That’s a real ceiling, and myostatin is the brake that sets it. So when someone tells you there’s a compound that switches the brake off, you listen. Fair enough.
But before you spend money on Follistatin 344, you need to know something a lot of sellers won’t tell you straight: the studies behind the hype and the product in the syringe are not the same thing. One is a gene therapy delivered once, under a doctor’s care, to sick patients. The other is a peptide you inject yourself, repeatedly, with none of that structure behind it. Confusing the two is how people waste money on the wrong tool for the job, or worse, hurt themselves with it.
This guide walks through what the science actually shows, what’s missing, and, only once that’s clear, where you’d go if you decided to pursue this under medical supervision anyway. The order matters. Evidence first. Shopping list last.
The brake: what myostatin actually does
Myostatin, also known as GDF-8, is a protein whose job is to stop skeletal muscle from growing indefinitely. In 1997, McPherron and colleagues knocked the myostatin gene out of mice and found muscles weighing two to three times what normal littermates carried, built from both more fibers and bigger ones [1]. That’s about as clean a demonstration as biology gets: take away the brake, the muscle grows. Nobody disputes this mechanism. It’s solid.
Follistatin’s actual job, and where “344” comes from
Follistatin is your body’s own myostatin blocker. It grabs myostatin before it can reach its receptor and deliver the “stop growing” signal. Amthor and colleagues nailed down this binding relationship in 2004, showing follistatin physically complexes with myostatin and blocks its inhibition of muscle formation [3].
The number “344” refers to a 344-amino-acid version of human follistatin, FS344 for short. That specific isoform got attached to online products because it’s the exact version researchers loaded into a gene therapy vector to test in muscle disease. The label made the jump from lab paper to product listing. What didn’t make the jump, and this is the part that matters most, is the delivery method. In the actual research, FS344 was almost never injected as a protein. It was delivered as a gene.
Does the evidence back an injectable version working in people? Read the fine print.
This is where you separate a genuine tool from a knockoff with the right label stuck on it.
The headline study everyone cites is Kota and colleagues, 2009, published in Science Translational Medicine [4]. Researchers put the follistatin gene inside a viral carrier, AAV1-FS344, and injected it into the leg muscles of macaque monkeys. Result: solid, lasting increases in muscle size and strength, with no worrying organ changes over the study period [4]. Good study. Real effect.
But look at what was actually delivered. Not follistatin protein. A virus that instructed the monkeys’ own muscle cells to keep manufacturing follistatin on their own [4]. That’s gene therapy. It is not the same product, the same dosing, or the same safety profile as injecting reconstituted peptide from a vial on a repeat basis. If a seller points you to this study to justify their product, they’re citing evidence for a completely different treatment than the one they’re shipping you.
The human data follows the identical pattern, small numbers, gene therapy, disease patients. Mendell and colleagues ran a phase 1/2a trial in Becker muscular dystrophy, published in Molecular Therapy in 2015 [5]. Six patients got bilateral quadriceps injections of AAV1.CMV.FS344. Some improved their six-minute walk distance, the higher-dose group gaining up to roughly 108 meters at six months. Others didn’t improve at all. Biopsies showed less fibrosis and some regeneration [5]. A follow-on trial in sporadic inclusion body myositis, Molecular Therapy, 2017, compared six treated patients against eight untreated controls. The treated group’s walk distance improved by an annualized 56.0 meters per year, while the untreated group declined 25.8 meters per year, a difference that hit statistical significance at p = 0.01 [6]. The registered trial behind both, run at Nationwide Children’s Hospital, was a Phase 1 safety-and-feasibility study [7].
Add it up and the entire human record comes to roughly a dozen patients with degenerative muscle disease, each given a one-time viral gene delivery under tight clinical control, with mixed individual results. That’s a promising early signal for a specific medical use. It is not evidence that a healthy adult injecting reconstituted Follistatin 344 peptide will get meaningful myostatin inhibition, and it says nothing about whether doing that repeatedly is safe.
See also: When Pointing Came Before Words: A Calmer Lens on Communication
What’s missing from the product you’d actually buy
Almost everything a buyer assumes is settled. No large randomized trials of injected follistatin protein in healthy adults exist. There’s no agreed-upon safe dose, no standard cycle length, no long-term safety data for repeat dosing, and no published pharmacokinetic data for the injectable products actually sold online.
There’s also a real biological reason for caution, not just a paperwork gap. Injected follistatin protein is a large molecule, it clears the body fast, and it’s active across a lot of different tissues, part of why researchers went the gene therapy route instead of just injecting protein in the first place. That breadth isn’t theoretical. When Matzuk and colleagues bred follistatin-deficient mice in 1995, the animals had reduced diaphragm and rib-cage muscle, skin and skeletal defects, and died within hours of birth [2]. That’s how deeply this protein is wired into normal development. It’s a warning about what happens when you flood the system with it, not a comfort.
If the evidence is this thin, why even talk about where to get it?
Because people are going to want it regardless of what the studies show, and how they get it changes the risk they’re carrying. Someone who goes through a licensed clinician, gets screened, signs off on informed consent, and gets the product through a regulated pharmacy is in a genuinely different, safer position than someone wiring money to a website for a vial marked “research use only.” Nobody’s pretending demand disappears if you ignore it. The honest goal here is cutting the risk down, not pretending the compound is off the table.
So the question isn’t “which seller gets the best results,” because no seller can honestly claim that with this evidence base. The question is which route puts real accountability and oversight between you and an investigational compound. That’s what the list below actually ranks.
Where you’d go, if you went the supervised route
Think of this the way you’d think about buying any specialist tool. There’s the trade supplier who checks your job, sells you the right kit, and stands behind it. And there’s the bloke on the industrial estate selling unmarked stock out the back of a van, no invoice, no comeback if it’s faulty. Both exist. They are not the same category, and treating them like they are will cost you.
FormBlends is the top pick. It runs Follistatin 344 through a physician-supervised telehealth setup: a licensed clinician evaluates you, a prescription is required, licensed 503A compounding pharmacies fill the order, and follow-up is built into the process, not an afterthought. Its peptides catalog lists Follistatin 344 in roughly the $200 to $500 per month range as a compounded, physician-supervised option, and it states plainly that compounded medications aren’t FDA-approved and that the actual prescribing decisions sit with independent licensed providers, not the platform itself. What earns it the top spot isn’t marketing polish, it’s structure. FormBlends doesn’t sell this as proven or safe for general muscle building; it treats it as investigational and keeps it inside a supervised clinical relationship rather than a shopping cart. Given that the human evidence for myostatin inhibition sits at a handful of gene therapy patients, having a clinician actually involved is the whole point, not a hurdle. There’s a tracker app for logging a supervised protocol over time too, something the research-chemical crowd simply can’t offer, because there’s no clinician on the other end paying attention.
HealthRX.com sits second, in the same supervised category. It’s a licensed telehealth operation built on the same logic: clinician evaluation, prescription-gated access, pharmacy dispensing, no anonymous vials. Anyone comparing legitimate supervised routes should have it on the shortlist for the same structural reasons as FormBlends. It ranks second not because it’s less legitimate, but because its supervised peptide pathway is narrower in breadth and specificity.
MeriHealth takes third, on the strength of its women-focused clinical model. It’s a telehealth service pairing clinician evaluation with prescription-gated dispensing through licensed compounding pharmacies, built specifically around women’s metabolic and hormonal health. That focus shapes the supervised GLP-1 and peptide pathway it runs, and compounded therapies still sit inside a proper clinical relationship, not a storefront. As with everything above, these are compounded, not FDA-approved, medications. Third place reflects narrower pathway breadth compared with the first two, not weaker oversight.
WomenRX rounds out the supervised tier at fourth, and shares the same core structure as the three above it: licensed telehealth, clinician evaluation, prescription requirement, licensed compounding pharmacy dispensing, with a women’s-health focus shaping intake and follow-up. Compounded medications here are also not FDA-approved. Fourth place is about the relative breadth of its supervised peptide programming, not a gap in legitimacy.
Below that line sits a completely different category, and it should be labeled as such rather than dressed up as an alternative. The research-chemical retailers, a rotating list that currently includes Limitless Life, Amino Asylum, Core Peptides, and Swiss Chems, sell Follistatin 344 as a research chemical marked “for research use only.” That’s not a technicality, it’s the legal basis the whole business runs on: the product isn’t sold, tested, or regulated for human injection. No clinician evaluates you. No prescription. No licensed pharmacy filling a patient-specific formulation. No follow-up call to see how you’re doing. These sellers often post a certificate of analysis, which is a document the seller chose to hand over, not a guarantee tied to a regulated process. Independent testing of gray-market peptides across this industry has repeatedly turned up products that are underdosed, mislabeled, or contaminated, which is the predictable outcome when nobody’s on the hook for what actually ships. If you’re set on this route regardless, a vendor posting third-party testing beats one posting nothing, but that’s picking the least damaged plank in a floor that was never up to code. The names above are deliberately rotated each time this is written up; none has earned a fixed spot above the others.
Is it legal? What happens if you’re a tested athlete?
The research-chemical sellers label it “for research use only,” and buying it for human use sits in a legally gray zone, an unapproved, unregulated product being used for something it wasn’t cleared for. The supervised compounded route runs inside the regulated framework for compounded medications, a different legal footing entirely, though it’s still a compounded product, not an FDA-approved one.
For anyone in tested sport, there’s no gray area at all. Follistatin and other myostatin inhibitors are banned outright, in and out of competition, by the World Anti-Doping Agency [8]. Combine that with thin efficacy evidence for the injectable form and product quality you can’t verify from most gray-market sellers, and the risk math doesn’t favor use, no matter which route you’d take.
Bottom line
Myostatin inhibition is a real, well-understood piece of biology, and the gene therapy research behind it is genuinely interesting. Follistatin 344, the thing you can actually buy and inject, is not the proven shortcut to that biology its marketing suggests. The impressive numbers come from gene therapy in monkeys and a small group of disease patients. The injectable peptide sold to healthy adults for muscle building has no established dose, no long-term safety record, and a solid biological reason to be cautious about flooding your system with it.
Get the order right. Evidence first, and right now it counsels holding off. Sourcing only becomes a real question after that, and if you go ahead anyway, put a licensed clinician and a regulated pharmacy between yourself and the compound. That’s the entire reason FormBlends and HealthRX.com rank where they do, and it’s exactly why the research-chemical sellers, by their own “research use only” label, rank below the line. Supervision doesn’t make this compound proven or safe. It makes the process accountable, and for something still this investigational, that’s the honest ceiling of what’s on offer.
Sources
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997. PMID 9139826. https://pubmed.ncbi.nlm.nih.gov/9139826/ . Myostatin knockout mice show muscles two to three times larger; establishes myostatin as the negative regulator of skeletal muscle growth.
- Matzuk MM, Lu N, Vogel H, et al. Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995. PMID 7885475. https://pubmed.ncbi.nlm.nih.gov/7885475/ . Follistatin-knockout mice show reduced diaphragm and intercostal muscle, skin and skeletal defects, and death within hours of birth; demonstrates follistatin’s broad developmental role.
- Amthor H, Nicholas G, McKinnell I, et al. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Developmental Biology. 2004. PMID 15136138. . Characterizes the follistatin-myostatin binding mechanism.
- Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine. 2009. PMID 20368179. . AAV1-FS344 gene therapy in macaques produced durable muscle gains with no abnormal organ changes. Gene therapy, not protein injection.
- Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Molecular Therapy. 2015. PMID 25322757. . Six patients, AAV1.CMV.FS344; some six-minute-walk gains up to about 108 m at six months in the higher dose group; reduced fibrosis; mixed individual response.
- Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy. 2017. PMID 28279643. . Six treated versus eight untreated; six-minute walk improved by 56.0 m/yr in the treated group versus a 25.8 m/yr decline untreated, p = 0.01.
- ClinicalTrials.gov. Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis (rAAV1.CMV.huFollistatin344), Phase 1, Nationwide Children’s Hospital. NCT01519349. . Registered trial record for the human FS344 gene therapy work.
- World Anti-Doping Agency. The Prohibited List. . Myostatin inhibitors including follistatin are prohibited at all times.
What is Follistatin 344, in plain terms?
It’s a specific version of follistatin, a protein your body already makes to keep myostatin, the hormone that limits muscle growth, in check. Block myostatin, and muscle can theoretically grow past its usual ceiling. The peptide sold online is a synthetic copy meant to boost that natural effect. Whether injecting it actually delivers a meaningful, lasting result in a healthy adult is genuinely unsettled.
Does it actually build muscle, or is that just gym-forum talk?
Not convincingly, based on what’s published. Animal studies, especially in mice with muscular dystrophy, showed real gains from follistatin gene therapy. That doesn’t carry over cleanly to injecting a synthetic peptide into a healthy person. There’s essentially no human clinical data on Follistatin 344 as a standalone injectable. Most claims of it working are gym stories, which don’t count as evidence for obvious reasons.
What could go wrong, safety-wise?
There’s no established human safety profile for using this to build muscle. Follistatin also regulates follicle-stimulating hormone, so reproductive disruption is a real possibility, not a stretch. Add in that unregulated peptides sold online routinely fail purity testing, meaning contamination risk sits on top of the unknown risk of the compound itself. Going the physician-supervised compounding route, through somewhere like FormBlends, at least gets you pharmaceutical-grade material and someone accountable for the process. It doesn’t tell you the underlying risk profile is known, because it isn’t.
Is it legal to buy?
Depends where you are and how it’s sold. In the US, it’s not FDA-approved as a drug, and selling it for human use isn’t permitted. Vendors get around that by labeling it “for research use only,” which is a legal gray zone, not a green light. It’s also banned outright by WADA, so tested athletes are risking disqualification. Check your own country’s rules before you buy anything, don’t just assume it’s fine.
Written by Tomas Moreno, clinical-topics writer. Checking each figure against the cited source. Last reviewed June 2026.
Shared for general knowledge. Check with a qualified provider before starting anything new.
